EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

BACKGROUND: Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4–12% of EGFR mutations and are generally refractory to the 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs). Development of effective therapies for patients with EGFRex20ins m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wenfeng, Huang, Yihua, Hong, Shaodong, Zhang, Zhonghan, Wang, Minghui, Gan, Jiadi, Wang, Wenjing, Guo, Honglin, Wang, Kai, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580637/
https://www.ncbi.nlm.nih.gov/pubmed/31208370
http://dx.doi.org/10.1186/s12885-019-5820-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580637/
https://www.ncbi.nlm.nih.gov/pubmed/31208370
http://dx.doi.org/10.1186/s12885-019-5820-0

Ejemplares similares